Pliant Therapeutics Director Flavia Borellini Receives 60,000-Share Award

What Happened

• Flavia Borellini, a director of Pliant Therapeutics (PLRX), received a grant of 60,000 derivative shares (transaction code A) on July 9, 2026. The reported acquisition price is $0.00, indicating an award/vesting-based grant rather than an open-market purchase or sale. This was a grant of a derivative security (likely RSUs or similar) rather than an immediate sale or cash exercise.

Key Details

• Transaction date and type: July 9, 2026 — Award/Grant of 60,000 derivative shares (code A); reported price $0.00.
• Vesting: Per the filing footnote, 1/36th of the shares vest and become exercisable on each monthly anniversary of July 9, 2026, subject to continued service.
• Shares owned after transaction: Not disclosed in the filing.
• Filing date/timeliness: Form 4 filed July 13, 2026 — appears to be filed within the normal two-business-day window following the transaction.
• Notes: This is a derivative award (not an immediate cash purchase or sale). No 10b5-1 plan, tax withholding, or cashless sale is reported in the filing.

Context

• Awards like this are common compensation for executives and directors and vest over time to encourage retention. Because the grant is a derivative award with monthly vesting, the shares are not immediately tradable until vested/settled; the grant itself should not be interpreted as an immediate buy or sell signal.